NCT04488653View on ClinicalTrials.gov

A Study to Determine the Safety and Efficacy of Oligopin® on Metabolic Risk Factors in Subjects With Metabolic Syndrome

NAUnknownINTERVENTIONAL

Enrollment

40

Participants

Timeline

Start Date

June 24, 2020

Primary Completion Date

October 19, 2021

Study Completion Date

January 10, 2022

Conditions

Metabolic Syndrome

Interventions

DIETARY_SUPPLEMENT

Oligopin®

French Maritime Pine Bark Extract - 100mg/day

DIETARY_SUPPLEMENT

Placebo

Maltodextrin

Trial Locations (1)

N6A5R8

KGK Science Inc., London

Sponsors

Collaborators (1)

KGK Science Inc.

All Listed Sponsors

collaborator

KGK Science Inc.

INDUSTRY

lead

Les Derives Resiniques et Terpeniques

INDUSTRY

NCT04488653 - A Study to Determine the Safety and Efficacy of Oligopin® on Metabolic Risk Factors in Subjects With Metabolic Syndrome | Biotech Hunter | Biotech Hunter